{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","groups":[{"description":"Participants received tivantinib 360 mg twice daily by mouth as monotherapy or combination therapy.","id":"OG000","title":"Tivantinib (Monotherapy or Combination)"}],"paramType":"NUMBER","populationDescription":"All participants who received ≥1 dose of study drug are included.","reportingStatus":"POSTED","timeFrame":"Up to 3021 days","title":"Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}